A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Tiotropium/BI 54903 FDC ethanolic inhalation solution via Respimat (doses of 1.23 µg/363.6 µg, 2.46 µg/363.6 µg or 4.93 µg/363.6 µg) versus free combination of Tiotropium aqueous inhalation solution via Respimat (doses of 0, 2.5 µg, 5 µg or 10 µg) plus BI 54903 ethanolic inhalation solution via Respimat (dose of 363.6 µg ) in patients with asthma.

Trial Profile

A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Tiotropium/BI 54903 FDC ethanolic inhalation solution via Respimat (doses of 1.23 µg/363.6 µg, 2.46 µg/363.6 µg or 4.93 µg/363.6 µg) versus free combination of Tiotropium aqueous inhalation solution via Respimat (doses of 0, 2.5 µg, 5 µg or 10 µg) plus BI 54903 ethanolic inhalation solution via Respimat (dose of 363.6 µg ) in patients with asthma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2017

At a glance

  • Drugs BI 54903/tiotropium bromide (Primary) ; Ciclesonide; Tiotropium bromide
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 11 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top